Navigation Links
VeraLight Announces CE Mark Approval of the SCOUT DS® for Noninvasive Diabetes Screening

ALBUQUERQUE, N.M., July 28, 2011 /PRNewswire/ -- VeraLight Inc., a privately held medical device company, today announced its SCOUT DS® Device was granted CE Mark approval for noninvasive diabetes screening. The easy to operate device needs no blood, does not require fasting, and yields an immediate result. The patient simply places their forearm onto the portable table-top unit and a quantitative result is reported in about three minutes.

Data from 421 study subjects in the CE filing shows SCOUT DS identified over 60% more people with abnormal glucose tolerance than either the fasting plasma glucose or hemoglobin A1c tests at thresholds established by The World Health Organization. The CE Mark filing was supported by safety and effectiveness studies on a cohort of 738 study subjects. SCOUT DS is Indicated for Use for the noninvasive screening of individuals 18 years or older who are at risk for prediabetes and/or type 2 diabetes to determine whether diagnostic testing is necessary. Prediabetes is defined as impaired glucose tolerance.

"SCOUT DS is an efficient, cost-effective alternative to established blood-based screening methods and we are excited to begin sales in key markets where the need for clinic-based and mass population screenings have been well-recognized by the national health systems and healthcare economists," says VeraLight CEO David Van Avermaete.  

SCOUT DS measures skin fluorescence using proprietary technology to detect biological markers found in skin related to cumulative glycemic exposure, oxidative stress and microvascular changes.   A proprietary algorithm adjusts for variations in skin tone and transforms the measured skin fluorescence and reflectance into a SCOUT Diabetes Score. Over 10,000 patients have been measured on the SCOUT DS during its technology development.

The CE Mark approval is proof of conformity that certifies the product meets European safety, effectiveness, and quality requirements. SCOUT DS received Health Canada Licence approval in April 2011 and VeraLight plans for an FDA filing in 2012.

VeraLight Secures $5 Million Series D Financing

VeraLight recently completed a Series D financing to support the SCOUT DS market rollout slated to begin later this year in Canada, India, the Middle East, and select European markets. The funding was led by Psilos Group and CMEA Capital, with participation by other existing investors, vSpring Capital and InLight Solutions.        

"The International Diabetes Federation projects that the prevalence of adults with diabetes will rise from 280 million to over 400 million by the year 2030. Type 2 diabetes accounts for at least 90% of all of these cases and is almost entirely preventable," said Lisa Suennen, Managing Member of Psilos Group and VeraLight Chairman of the Board. "Countries around the world are struggling to find an economical and practical way to screen their citizens for Type 2 diabetes early when there is still time to avoid the disease.  The VeraLight SCOUT DS device is the first product we have seen to enable widespread screening for diabetes that is inexpensive, bloodless, non-fasting, and is more sensitive than cumbersome blood testing.  This is an important product to address a critical public health issue and we are delighted to be involved with it."

About VeraLight

VeraLight is a privately held medical instrumentation company led by former Johnson & Johnson executive, David Van Avermaete. The company's mission is to help stem the tide of the global diabetes epidemic through early detection of the more than 500 million individuals who have undiagnosed diabetes or impaired glucose tolerance, thus enabling initiation of therapies that can prevent diabetes or reduce its complications and associated costs. The company is headquartered in Albuquerque, New Mexico.   For more information and a product video see

About Psilos Group

Psilos Group Managers, LLC ("Psilos") is a healthcare investment firm focused on providing venture and growth capital to companies operating in the healthcare economy. The firm believes that successful healthcare innovation must reduce cost, improve quality, and align incentives across payers, providers and patients. Founded in 1998, Psilos has $580 million under management and invests across three core healthcare sectors: healthcare services, healthcare information technology and medical technology. Funds managed by Psilos have invested in companies such as ActiveHealth, AngioScore, Definity Health, HealthEdge, Extend Health, Mauna Kea Technologies, and VeraLight, among many others, which have played, and continue to play, key roles in the transformation of the U.S. healthcare economy. Psilos has offices in New York, the San Francisco Bay Area, and in Santa Fe, New Mexico. For more information, go to

About CMEA Capital

CMEA Capital provides capital to entrepreneurs and investors in the life sciences, energy & materials, and information technology sectors. Through its combination of solid scientific credentials and seasoned management expertise, CMEA identifies, funds and manages new businesses based on the emerging, interdisciplinary science required to meet the challenges and opportunities of a rapidly changing global economy. The firm currently manages seven funds representing investments in excess of $1 billion. CMEA has been an early stage investor in many leading companies, including Flextronics, Symmx, Codexis, Maxygen, A123 Systems, Entropic, Silicon Spice, Pixazza, Blekko, and Jobvite.

Janet Garcia

SOURCE VeraLight Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
2. Boston Scientific Announces $1.0B Share Repurchase Program
3. China Nuvo Solar Target Acquisition SurgLine Announces Third-Party Distribution Agreement With OptiMedical, Corp.
4. Streamline Health Announces Two Clients Have Contracted for Multiple Integrations to Their Epic Systems
5. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
6. West Announces Second Quarter 2011 Results
7. Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress
8. PDL BioPharma Announces Second Quarter 2011 Financial Results
9. BD Announces Agreement to Acquire Carmel Pharma, Inc.
10. Boston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion
11. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
(Date:11/26/2015)... -- ) has announced the ... Viscosity Drugs" report to their offering. ... of the "Self Administration of High Viscosity ... Research and Markets ( ) has ... of High Viscosity Drugs" report to their ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Marker Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Dr. John ... to learn more about hair loss treatment with the Capillus272™ Pro laser therapy cap. ... solution for thicker and fuller hair, without the need for surgery, prescription pills, or ...
(Date:11/25/2015)... , ... November 25, 2015 , ... For the first ... “ Two Organizations, One Beat ” campaign. The partnership between the two groups began ... aid in MAP International’s cause. , MAP International was founded in 1954 and is ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like to become ... invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will ... , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio ...
(Date:11/25/2015)... ... 25, 2015 , ... The McHenry County law firm of Botto Gilbert ... Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the ... App (2d) 130884WC. , According to court documents, Adcock testified that on May 10, ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... a double board certified facial plastic surgeon specializing in both surgical and non-surgical ... of The Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained ...
Breaking Medicine News(10 mins):